Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: December 2014

2 - Clinical aspects of dementia

References

1. M. Prince, R. Bryce, E. Albanese, et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63–75.e2.
2. J. B. Langbaum, A. S. Fleisher, K. Chen, et al. Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol 2013; 9: 371–81.
3. J. S. Goldman, S. E. Hahn, J. W. Catania, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011; 13: 597–605.
4. L. Alves, A. S. Correia, R. Miguel, P. Alegria, P. Bugalho. Alzheimer’s disease: a clinical practice-oriented review. Front Neurol 2012; 3: 63.
5. A. C. Naj, G. Jun, G. W. Beecham, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 2011; 43: 436–41.
6. D. Harold, R. Abraham, P. Hollingworth, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 2009; 41: 1088–93.
7. J. C. Lambert, S. Heath, G. Even, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet 2009; 41: 1094–9.
8. S. Seshadri, A. L. Fitzpatrick, M. A. Ikram, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303: 1832–40.
9. P. Hollingworth, D. Harold, R. Sims, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011; 43: 429–35.
10. K. D. Coon, A. J. Myers, D. W. Craig, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer’s disease. J Clin Psychiatry 2007; 68: 613–8.
11. G. McKhann, D. Drachman, M. Folstein, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44.
12. G. M. McKhann, D. S. Knopman, H. Chertkow, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263–9.
13. A. P. Duker, A. J. Espay, Z. K. Wszolek, et al. Atypical motor and behavioral presentations of Alzheimer disease: a case-based approach. Neurologist 2012; 18: 266–72.
14. N. Kouri, J. L. Whitwell, K. A. Josephs, R. Rademakers, D. W. Dickson. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011; 7: 263–72.
15. A. Hassan, J. L. Whitwell, K. A. Josephs. The corticobasal syndrome–Alzheimer’s disease conundrum. Expert Rev Neurother 2011; 11: 1569–78.
16. D. F. Tang-Wai, N. R. Graff-Radford, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004; 63: 1168–74.
17. S. J. Crutch, M. Lehmann, J. M. Schott, et al. Posterior cortical atrophy. Lancet Neurol 2012; 11: 170–8.
18. Y. Jung, J. R. Duffy, K. A. Josephs. Primary progressive aphasia and apraxia of speech. Semin Neurol 2013; 33: 342–7.
19. J. L. Whitwell, C. R. Jack, Jr., J. R. Duffy, et al. Microbleeds in the logopenic variant of primary progressive aphasia. Alzheimers Dement 2013: 10: 62–6.
20. K. A. Johnson, N. C. Fox, R. A. Sperling, W. E. Klunk. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006213.
21. H. Braak, E. Braak. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–59.
22. R. Sperling, K. Johnson. Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria. Continuum (Minneap Minn) 2013; 19: 325–38.
23. J. B. Langbaum, K. Chen, W. Lee, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neuroimage 2009; 45: 1107–16.
24. C. M. Clark, J. A. Schneider, B. J. Bedell, et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 2011; 305: 275–83.
25. K. Blennow, E. Vanmechelen. CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 2003; 61: 235–42.
26. L. Mucke, D. J. Selkoe. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012; 2: a006338.
27. I. McKeith, J. Mintzer, D. Aarsland, et al. Dementia with Lewy bodies. Lancet Neurol 2004; 3: 19–28.
28. L. Hansen, D. Salmon, D. Galasko, et al. The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology 1990; 40: 1–8.
29. T. J. Ferman, G. E. Smith, B. F. Boeve, et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer’s disease. Clin Neuropsychol 2006; 20: 623–36.
30. I. G. McKeith, D. Galasko, K. Kosaka, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–24.
31. I. G. McKeith, D. W. Dickson, J. Lowe, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–72.
32. J. L. Cummings. Fluctuations in cognitive function in dementia with Lewy bodies. Lancet Neurol 2004; 3: 266.
33. M. P. Walker, G. A. Ayre, J. L. Cummings, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology 2000; 54: 1616–25.
34. T. J. Ferman, G. E. Smith, B. F. Boeve, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004; 62: 181–7.
35. U. P. Mosimann, E. N. Rowan, C. E. Partington, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with lewy bodies. Am J Geriatr Psychiatry 2006; 14: 153–60.
36. D. J. Burn, E. N. Rowan, T. Minett, et al. Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord 2003; 18: 884–9.
37. S. B. Bonelli, G. Ransmayr, M. Steffelbauer, et al. L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia. Neurology 2004; 63: 376–8.
38. G. Ransmayr, K. Seppi, E. Donnemiller, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson’s disease. Eur J Nucl Med 2001; 28: 1523–8.
39. B. F. Boeve, M. H. Silber, T. J. Ferman. REM sleep behavior disorder in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17: 146–57.
40. I. McKeith, A. Fairbairn, R. Perry, P. Thompson, E. Perry. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Bmj 1992; 305: 673–8.
41. D. Aarsland, K. Andersen, J. P. Larsen, A. Lolk, P. Kragh-Sorensen. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: 387–92.
42. D. Aarsland, I. Litvan, D. Salmon, et al. Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003; 74: 1215–20.
43. R. Watson, A. M. Blamire, J. T. O’Brien. Magnetic resonance imaging in lewy body dementias. Dement Geriatr Cogn Disord 2009; 28: 493–506.
44. J. T. O’Brien, S. Paling, R. Barber, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001; 56: 1386–8.
45. S. Minoshima, N. L. Foster, A. A. Sima, et al. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50: 358–65.
46. Z. Walker, D. C. Costa, R. W. Walker, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73: 134–40.
47. E. Ratnavalli, C. Brayne, K. Dawson, J. R. Hodges. The prevalence of frontotemporal dementia. Neurology 2002; 58: 1615–21.
48. C. Lomen-Hoerth, T. Anderson, B. Miller. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59: 1077–9.
49. J. S. Snowden, N. A. Austin, S. Sembi, et al. Emotion recognition in Huntington’s disease and frontotemporal dementia. Neuropsychologia 2008; 46: 2638–49.
50. O. Piguet, M. Hornberger, E. Mioshi, J. R. Hodges. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011; 10: 162–72.
51. O. Piguet, A. Petersen, B. Yin Ka Lam, et al. Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol 2011; 69: 312–9.
52. T. W. Chow, A. A. Alobaidy. Incorporating new diagnostic schemas, genetics, and proteinopathy into the evaluation of frontotemporal degeneration. Continuum (Minneap Minn) 2013; 19: 438–56.
53. J. M. Harris, C. Gall, J. C. Thompson, et al. Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. Neurology 2013; 80: 1881–7.
54. D. Neary, J. S. Snowden, L. Gustafson, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546–54.
55. K. Rascovsky, J. R. Hodges, D. Knopman, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456–77.
56. E. Mioshi, C. M. Kipps, K. Dawson, et al. Activities of daily living in frontotemporal dementia and Alzheimer disease. Neurology 2007; 68: 2077–84.
57. A. Graham, R. Davies, J. Xuereb, et al. Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain 2005; 128: 597–605.
58. H. J. Rosen, M. L. Gorno-Tempini, W. P. Goldman, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002; 58: 198–208.
59. C. Davatzikos, S. M. Resnick, X. Wu, P. Parmpi, C. M. Clark. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage 2008; 41: 1220–7.
60. J. L. Whitwell, J. Xu, J. Mandrekar, et al. Frontal asymmetry in behavioral variant frontotemporal dementia: clinicoimaging and pathogenetic correlates. Neurobiol Aging 2013; 34: 636–9.
61. J. Barnes, J. L. Whitwell, C. Frost, et al. Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. Arch Neurol 2006; 63: 1434–9.
62. K. A. Josephs, J. L. Whitwell, J. E. Parisi, et al. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol 2010; 17: 969–75.
63. J. L. Whitwell, C. R. Jack, Jr., J. E. Parisi, et al. Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. J Mol Neurosci 2011; 45: 372–8.
64. T. Kanda, K. Ishii, T. Uemura, et al. Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies. Eur J Nucl Med Mol Imaging 2008; 35: 2227–34.
65. A. R. Varma, W. Adams, J. J. Lloyd, et al. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer’s disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 2002; 105: 261–9.
66. M. M. Mesulam. Slowly progressive aphasia without generalized dementia. Ann Neurol 1982; 11: 592–8.
67. M. L. Gorno-Tempini, A. E. Hillis, S. Weintraub, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006–14.
68. M. M. Mesulam. Primary progressive aphasia–a language-based dementia. N Engl J Med 2003; 349: 1535–42.
69. M. M. Mesulam. Primary progressive aphasia. Ann Neurol 2001; 49: 425–32.
70. M. Grossman. The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurol 2012; 11: 545–55.
71. J. R. Duffy. Apraxia of speech in degenerative neurologic disease. Aphasiology 2006; 20: 511–27.
72. M. R. McNeil, D. A. Robin, R. A. Schmidt. Apraxia of Speech: Definition and Differential Diagnosis. New York: Thieme. 2009.
73. K. A. Josephs, J. R. Duffy, E. A. Strand, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129: 1385–98.
74. E. Rogalski, D. Cobia, T. M. Harrison, et al. Progression of language decline and cortical atrophy in subtypes of primary progressive aphasia. Neurology 2011; 76: 1804–10.
75. M. L. Gorno-Tempini, N. F. Dronkers, K. P. Rankin, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55: 335–46.
76. S. Bozeat, M. A. Ralph, K. Patterson, J. R. Hodges. The influence of personal familiarity and context on object use in semantic dementia. Neurocase 2002; 8: 127–34.
77. J. R. Hodges, K. Patterson, S. Oxbury, E. Funnell. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain 1992; 115: 1783–806.
78. C. M. Kipps, R. R. Davies, J. Mitchell, et al. Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord 2007; 23: 334–42.
79. S. M. Wilson, M. L. Henry, M. Besbris, et al. Connected speech production in three variants of primary progressive aphasia. Brain 2010; 133: 2069–88.
80. C. J. Mummery, K. Patterson, C. J. Price, et al. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 2000; 47: 36–45.
81. M. L. Gorno-Tempini, S. M. Brambati, V. Ginex, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology 2008; 71: 1227–34.
82. J. D. Rohrer, F. Caso, C. Mahoney, et al. Patterns of longitudinal brain atrophy in the logopenic variant of primary progressive aphasia. Brain Lang 2013; 127: 121–6.
83. J. L. Whitwell, V. J. Lowe, J. R. Duffy, et al. Elevated occipital β-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. J Neurol Neurosurg Psychiatry 2013; 84: 1357–64.
84. B. F. Boeve, A. E. Lang, I. Litvan. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54 (Suppl. 5): S15–9.
85. M. J. Armstrong, I. Litvan, A. E. Lang, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80: 496–503.
86. J. J. Rebeiz, E. H. Kolodny, E. P. Richardson, Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18: 20–33.
87. W. R. Gibb, P. J. Luthert, C. D. Marsden. Corticobasal degeneration. Brain 1989; 112: 1171–92.
88. C. M. Frattali, J. Grafman, N. Patronas, F. Makhlouf, I. Litvan. Language disturbances in corticobasal degeneration. Neurology 2000; 54: 990–2.
89. R. Murray, M. Neumann, M. S. Forman, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology 2007; 68: 1274–83.
90. W. A. Vanvoorst, M. C. Greenaway, B. F. Boeve, et al. Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy. Parkinsonism Relat Disord 2008; 14: 376–8.
91. G. K. Wenning, I. Litvan, J. Jankovic, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998; 64: 184–9.
92. A. Hassan, J. L. Whitwell, B. F. Boeve, et al. Symmetric corticobasal degeneration (S-CBD). Parkinsonism Relat Disord 2010; 16: 208–14.
93. J. C. Steele, J. C. Richardson, J. Olszewski. Progressive supranuclear palsy. a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333–59.
94. K. A. Josephs, R. C. Petersen, D. S. Knopman, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66: 41–8.
95. B. F. Boeve. Progressive supranuclear palsy. Parkinsonism Relat Disord 2012; 18 (Suppl. 1): S192–4.
96. A. D. Cooper, K. A. Josephs. Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: a prospective study. Parkinsonism Relat Disord 2009; 15: 59–61.
97. M. L. Albert, R. G. Feldman, A. L. Willis. The ‘subcortical dementia’ of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37: 121–30.
98. D. R. Williams, A. J. Lees. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8: 270–9.
99. M. Vidailhet, S. Rivaud, N. Gouider-Khouja, et al. Eye movements in parkinsonian syndromes. Ann Neurol 1994; 35: 420–6.
100. H. S. Markus, A. J. Lees, G. Lennox, C. D. Marsden, D. C. Costa. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson’s disease and normal controls. Mov Disord 1995; 10: 179–87.
101. I. M. Coulier, J. J. de Vries, K. L. Leenders. Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration? Mov Disord 2003; 18: 1175–8.
102. J. L. Whitwell, C. R. Jack, Jr., J. E. Parisi, et al. Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology. Eur J Neurol 2013; 20: 1417–22.
103. L. A. Massey, H. R. Jager, D. C. Paviour, et al. The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy. Neurology 2013; 80: 1856–61.
104. H. Botha, J. L. Whitwell, A. Madhaven, et al. The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism Relat Disord 2013: 20: 180–5.
105. K. A. Josephs, J. L. Whitwell, D. W. Dickson, et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008; 29: 280–9.
106. K. Groschel, T. K. Hauser, A. Luft, et al. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage 2004; 21: 714–24.
107. M. D. Geschwind, H. Shu, A. Haman, J. J. Sejvar, B. L. Miller. Rapidly progressive dementia. Ann Neurol 2008; 64: 97–108.
108. K. A. Josephs, J. E. Ahlskog, J. E. Parisi, et al. Rapidly progressive neurodegenerative dementias. Arch Neurol 2009; 66: 201–7.
109. R. T. Johnson. Prion diseases. Lancet Neurol 2005; 4: 635–42.
110. K. A. Josephs, D. S. Knopman, J. L. Whitwell, et al. Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLD-U vs FTLD-MND. Neurology 2005; 65: 645–7.